Table 1. Background characteristics of the 12 patients in whom examination was performed for gene abnormalities.

No	Age	Sex	BI	Histology	T	N	M	Stage	PS	EGFR	EML4-ALK	1st line	2nd line	Outcome	Survival time
1	33	m	10	adeno	4	0	1	IV	1	+	n.d.	CBDCA+TXL	Gefitinib	death	1,208 days
2	37	m	800	adeno	4	2	1	IV	1	+	n.d.	Gefitinib	CBDCA+TXL	death	461 days
3	37	m	450	adeno	4	3	1	IV	3	+	n.d.	CBDCA+TXL	Gefitinib	death	379 days
4	39	m	400	adeno	3	3	1	IV	0	+	n.d.	CDDP+PEM	Gefitinib	death	364 days
5	31	f	100	adeno	1	3	0	IIIB	0	±	n.d.	CBDCA+TXL	Gefitinib	alive	2,688+α
6	35	f	0	adeno	4	0	0	IIIB	0	-	+	CBDCA+GEM	PEM	alive	1,456+α
7	37	f	0	adeno	2	1	1	IV	0	-	+	CBDCA+PEM		alive	757+α
8	34	f	0	adeno	4	3	1	IV	2	-	+	CBDCA+TXL	GEM	death	568 days
9	33	m	300	adeno	4	3	1	IV	1	-	+	CBDCA+TXL	CBDCA+PEM	death	175 days
10	35	m	0	adeno	4	3	1	IV	1	-	+	CBDCA+TXL	CBDCA+PEM	death	99 days
11	37	f	0	adeno	2	2	0	IIIA	0	-	-	CBDCA+TXL		alive	365+α
12	36	m	340	non-small	2b	3	1b	IV	1	-	-	CBDCA+TXL		alive	280+α

Abbreviations: BI, brinkman index; PS, performance status; ±, EGFR mutaion indeterminate, but responded to gefitinib; n.d., not done; CBDCA, carboplatin; TXL, pacritaxicel; PEM, pemetrexed; GEM, gemcitabine.